Mode and site of action of therapies targeting CGRP signaling

Labastida Ramírez, Alejandro; GOLLION, Cedric; Stanyer, Emily; Dapkute, Austeja; Braniste, Diana; Caronna, Edoardo

View

Mode and site of action of therapies targeting CGRP signaling, 2023 (1.300Mb)

Author

Labastida Ramírez, Alejandro

Date

2023-09-11

Permanent link

https://hdl.handle.net/11351/10308

DOI

10.1186/s10194-023-01644-8

ISSN

1129-2377

WOS

001061857100001

PMID

37691118

Show full item record

Abstract

Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed.

Keywords

Calcitonin; Headache; Migraine

Bibliographic citation

Labastida-Ramírez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D, et al. Mode and site of action of therapies targeting CGRP signaling. J Headache Pain. 2023 Sep 11;24:125.